Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Moderate to Severe Plaque Psoriasis With or Without Psoriatic Arthritis
CTR20170035Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, psoriatic arthritis (PsA), sponsored by Novartis. Started Feb 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on CTR20170035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170035.